기사 (3건) 리스트형 웹진형 타일형 Daewoong Pharma, Nabota 3Q Cumulative Sales KRW 113.3 billion...Overseas Sales 83% Occupied Daewoong Pharma, Nabota 3Q Cumulative Sales KRW 113.3 billion...Overseas Sales 83% Occupied Daewoong Pharmaceutical(Daewoong) announced on the 14th that, of the cumulative sales of Nabota (the U.S. name is Jeuveau) of KRW 113.3 billion as of the third quarter of this year, overseas sales were calculated to be KRW 93.5 billion (83%). Nabota is the No.1 exporter of domestic toxin products.Th 인터뷰·칼럼 | BK Min, 박성재 | 2023-11-14 14:32 Daewoong Pharmaceutical "Nabota, High-dose Administration Clinical trial →Long-lasting effect proved" Daewoong Pharmaceutical "Nabota, High-dose Administration Clinical trial →Long-lasting effect proved" Daewoong Pharmaceutical announced on the 3rd that the botulinum toxin Nabota (Export name Jubo, The U.S.) had obtained positive interim results for long-lasting effects in high-dose clinical trials for patients with frown lines.An American partner, Evolus announced the interim results(Extra Strength 인터뷰·칼럼 | BK Min | 2023-02-03 14:39 [Industry Analysis] Daewoong Pharmaceutical's overseas business is expected to grow rapidly...Expectations for the global launch of two new drugs [Industry Analysis] Daewoong Pharmaceutical's overseas business is expected to grow rapidly...Expectations for the global launch of two new drugs Daewoong Pharmaceutical's gastroesophageal reflux treatment (FEXUCLUE, expected to be sold in the fourth quarter of 2022) and diabetes treatment (enavogliflozin, expected to be released in the second half of 2023) are drugs with the latest mechanism of action, and the prescription rate in the relate 인터뷰·칼럼 | BK Min | 2022-11-25 12:33 처음처음1끝끝